Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases.

CTP-692

A promising first-in-class approach to broaden the scope of treating schizophrenia

CTP-543

A drug candidate for alopecia areata, a disease with no currently-approved treatments

LATEST NEWS

Aug 06, 2020
Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update

Jul 30, 2020
Concert Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 6, 2020

© 2020 Concert Pharmaceuticals. All rights reserved.
HOME | SITEMAP | CONTACT | TERMS OF USE | PRIVACY POLICY
Back to Top